CD40 Ligand Gene Therapy Shows Promise in Treating Aggressive Bladder Cancer

Researchers at Uppsala University in Sweden have been investigating the potential of CD40 ligand (CD40L) gene therapy in treating aggressive bladder cancer. Their study, published in the Journal of Immunotherapy, involved using adenoviral vectors to deliver the CD40L gene into the bladder of mice with disseminated cancer. The results showed a significant increase in overall survival of tumor-bearing mice and complete eradication of bladder tumors and lung metastases in some cases. The researchers concluded that CD40L gene therapy is a potent treatment option for disseminated cancer by activating T cells and controlling tumor cell growth and viability.

Key Takeaways:

• CD40L gene therapy showed a significant increase in overall survival of tumor-bearing mice, with a mean of 18.5 days compared to 13 days in control mice.
• Bladder tumors were eradicated in 2 out of 10 mice treated with AdCD40L gene therapy, while lung metastases were cleared in 6 out of 10 mice.
• Tumor-infiltrating effector T cells in AdCD40L-treated mice were cytotoxic (CD107a+), indicating activation of T cells.
• AdCD40L gene therapy induced cell growth inhibition and cell death in MB49 tumor cells in vitro and in vivo.
• However, the effect was not potent enough to cure growing tumors in immunodeficient mice.

Statistics:

• Mean overall survival of tumor-bearing mice treated with AdCD40L gene therapy: 18.5 days
• Overall survival of control mice: 13 days
• Bladder tumors eradicated: 2 out of 10 mice
• Lung metastases cleared: 6 out of 10 mice
• Tumor-infiltrating effector T cells cytotoxic: 100% in AdCD40L-treated mice, 0% in control mice

Sources:

• Lindqvist C, et al. Local AdCD40L Gene Therapy is Effective for Disseminated Murine Experimental Cancer by Breaking T-cell Tolerance and Inducing Tumor Cell Growth Inhibition. Journal of Immunotherapy, 2009;32(8):785-792.
• Cancer Gene Therapy Week editors. Copyright 2009, Cancer Gene Therapy Week via NewsRx.com.